Peptides immunoreactive with autoantibodies from patients...

Chemistry: analytical and immunological testing – For preexisting immune complex or auto-immune disease – Rheumatoid factors

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100, C435S007920, C530S326000, C530S388250, C530S389300

Reexamination Certificate

active

06858438

ABSTRACT:
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detection autoimmune antibodies.

REFERENCES:
patent: 5888833 (1999-03-01), Serre et al.
patent: WO95 34312 (1995-12-01), None
patent: WO9935617 (1999-07-01), None
Abaza et al., J. Biol. Chem. 11(5):433-444, 1992.*
Tarsca, E et al. J. Biol. Chem. (Nov., 1996) 271(48):30709-30716.*
Girbal-Neuhauser, Elisabeth, et al., “The Epitopes Targeted by the Rheumatoid Arthritis-Associated Antifilaggrin Autoantibodies are Posttranslationally Generatedon Various Sites of (Pro)Filaggrin by Deimination of Arginine Residues,”J of Immunology, vol. 162, pp 585-594 (1999).
Schellekens, G.A., et al., “Citrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis-Specific Autoantibodies,”J. Clin. Invest.vol. 101, No. 1, pp 273-281 (Jan. 1998).
Shellekens, G.A., et al., “The Diagnostic Properties of Rheumatoid Arthritis Antibodies Recognizing a Cyclic Citrullinated Peptide,”Arthritis&Rheumatism, vol. 43, No. 1, pp 155-163 (Jan. 2000).
Van Jaarsveld, C.H.M., et al., “The Prognostic Value of the Antiperinuclear Factor, Anti-Citrullinated Peptide Antibodies and Rheumatoid Factor in Early Rheumatoid Arthritis,”Clinical and Experimental Rheumatologyvol. 17, pp 689-697 (1999).
Gan, Song-Qing, “Organization, Structure, and Polymorphisms of the Human Profilaggrin Gene,”Biochemistry, vol. 29, No. 40, pp 9432-9440 (Oct. 9, 1990).
Hoet, R.M.A., et al., “Antiperinuclear Factor, a Marker Autoantibody for Rheumatoid Arthritis: Colocalixstion of the Perinuclear Factor and Profilaggrin,”Annals of the Rheumatic Diseases, vol. 50, No. 9, Loden, Great Britain (Sep. 1991)p. 611-614.
Misaki, Y., et al., “The 56K Autontigen is Identical to Human Annexin XI”,Journal of Biological Chemistry, vol. 269, No. 6, Baltimore MD, pp 4240-4246 (Feb. 11, 1994).
Seggag, M., et al., “The Antiperinuclear Factor and the So-Called Antikeratin antibodies Are the Same Rheumatoid Arthritis—Specific Autoantibodies,”Journal of Clinical investigation, vol. 95, No. 6, New York NY (Jun. 1995) p 2672-2679.
Simon, M., et al., “The Cyokeratin Filament-Aggregating Protein Filaggrin is the Target of the So-called ‘Antikeratin Antibodies,’ Autoantibodies Specific for Rheumatoid Arthritis,”Journal of Clinical Investigation, vol. 92, No. 3, pp 1387-1393 New York NY (Sep. 1993).
Shellenkens, G.A., et al., “The Modified Arginine residue Citrulline is the Major Constituent of Epitopes Recognized by Autoantibodies in Sera from Rheumatoid Arthritis Patients,”Arthritis and Rheumatism, vol. 40, No. 9, p. S276, New York NY (Nov. 8-12, 1997).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Peptides immunoreactive with autoantibodies from patients... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides immunoreactive with autoantibodies from patients..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides immunoreactive with autoantibodies from patients... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3476658

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.